Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 11/20 | 0.34 |
| ▸ | JAK2 | O60674 | 8/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31443759 | 1.00 | SCN9A (0.36) | SCN9AHCRTR2NTRK1JAK2 | |
| SCHEMBL31443660 | 0.97 | SCN9A (0.34) | SCN9AHCRTR2NTRK1JAK2 | |
| SCHEMBL31443515 | 0.93 | SCN9A (0.38) | SCN9AHCRTR2NTRK1JAK2 | |
| SCHEMBL31443644 | 0.93 | SCN9A (0.38) | SCN9AHCRTR2NTRK1JAK2 | |
| SCHEMBL31444452 | 0.93 | SCN9A (0.38) | SCN9AHCRTR2NTRK1JAK2 | |
| SCHEMBL31443841 | 0.93 | SCN9A (0.38) | SCN9AHCRTR2NTRK1JAK2 | |
| SCHEMBL31443635 | 0.91 | SCN9A (0.36) | SCN9ANTRK1JAK2 | |
| SCHEMBL31443452 | 0.91 | SCN9A (0.36) | SCN9ANTRK1JAK2 | |
| SCHEMBL31443609 | 0.91 | SCN9A (0.35) | SCN9AHCRTR2NTRK1JAK2 | |
| SCHEMBL31443703 | 0.91 | SCN9A (0.35) | SCN9AHCRTR2NTRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | claimed |
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |